Medicare to Negotiate Prices on 15 More Drugs

Medications for diabetes, HIV, arthritis among those selected for federal price negotiations.

Jan. 27, 2026 at 7:47pm

Got story updates? Submit your updates here. ›

The Trump administration announced 15 new medications that will be subject to Medicare price negotiations, including drugs that treat Type 2 diabetes, HIV, and arthritis. The negotiations are part of a 2022 law that allows the federal government to directly negotiate drug prices with manufacturers, with the goal of delivering significant savings to taxpayers.

Why it matters

This latest round of price negotiations has the potential to lower costs for some of Medicare's most expensive prescription drugs, which could provide relief to seniors and taxpayers who have faced rising drug prices. The program aims to target the most costly medications used by older Americans.

The details

The 15 drugs selected for negotiation this year include popular medications like the Type 2 diabetes drug Trulicity, the HIV treatment Biktarvy, and the wrinkle-reducing drug Botox. In total, over 1.8 million Medicare enrollees used these 15 drugs in the past year, accounting for about 6% of total Part B and Part D spending. One previously negotiated diabetes drug, Tradjenta, will also undergo renegotiation.

  • The federal government had until February 1, 2026 to announce the list of 15 drugs.
  • The negotiated prices for these 15 drugs will go into effect in 2028.

The players

Centers for Medicare and Medicaid Services (CMS)

The federal agency that oversees the Medicare program and announced the 15 drugs selected for price negotiations.

Dr. Mehmet Oz

The CMS Administrator who stated that the negotiations will help target the most expensive drugs in Medicare and ensure the system works for patients, not special interests.

Pharmaceutical Research and Manufacturers of America (PhRMA)

The leading trade association for pharmaceutical companies, which criticized the Inflation Reduction Act that authorized the Medicare drug price negotiation program.

AARP

The advocacy group for older Americans, whose CEO Dr. Myechia Minter-Jordan called the announcement a 'significant step forward' in lowering drug prices for Medicare enrollees.

Got photos? Submit your photos here. ›

What they’re saying

“For too long, seniors and taxpayers have paid the price for skyrocketing prescription drug costs. Under President Trump's leadership, CMS is taking strong action to target the most expensive drugs in Medicare, negotiate fair prices, and make sure the system works for patients — not special interests.”

— Dr. Mehmet Oz, CMS Administrator (wral.com)

“Older Americans across the political spectrum consistently say that lowering drug prices is a top priority, and we thank the Administration for protecting Medicare's ability to meet that need.”

— Dr. Myechia Minter-Jordan, AARP CEO (wral.com)

“The IRA continues to show why government price setting is the wrong approach for Americans.”

— Elizabeth Carpenter, PhRMA Executive Vice President of Policy and Research (wral.com)

What’s next

The negotiated prices for these 15 drugs will go into effect in 2028, providing potential savings for Medicare enrollees and taxpayers.

The takeaway

This latest round of Medicare drug price negotiations aims to lower costs for some of the program's most expensive medications, continuing efforts to make prescription drugs more affordable for seniors and the government.